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Abstract
BACKGROUND—Degludec is an ultralong-acting, once-daily basal insulin that is approved for 
use in adults, adolescents, and children with diabetes. Previous open-label studies have shown 
lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia 
among patients who received degludec than among those who received basal insulin glargine. 
However, data are lacking on the cardiovascular safety of degludec.
METHODS—We randomly assigned 7637 patients with type 2 diabetes to receive either insulin 
degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and 
bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary 
composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major 
cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal 
stroke) with a prespecified non-inferiority margin of 1.3. Adjudicated severe hypoglycemia, as 
defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted 
secondary outcome.
RESULTS—Of the patients who underwent randomization, 6509 (85.2%) had established 
cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, 
the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 
8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 
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patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 
95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean 
glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose 
level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 
mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients 
(4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 
1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for 
superiority). Rates of adverse events did not differ between the two groups.
CONCLUSIONS—Among patients with type 2 diabetes at high risk for cardiovascular events, 
degludec was noninferior to glargine with respect to the incidence of major cardiovascular events.
Cardiovascular complications remain two to four times more common among patients with 
type 2 diabetes than among persons without diabetes.1 Observational studies have suggested 
that patients with type 2 diabetes who require insulin have increased rates of cardiovascular 
events.1–3 However, a large clinical trial involving patients with impaired fasting glucose 
levels, impaired glucose tolerance, or type 2 diabetes reported cardiovascular outcomes 
among those who received basal insulin glargine that were similar to outcomes among 
patients who received standard care.4
Degludec is an ultralong-acting, once-daily basal insulin approved for use in adults, 
adolescents, and children with diabetes.5–7 Previous open-label studies have shown lower 
day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among 
the patients who received degludec than among those who received glargine.8,9 The Food 
and Drug Administration (FDA) required that a dedicated preapproval trial of cardiovascular 
outcomes be conducted to assess the cardiovascular safety of degludec, as compared with 
glargine. Consequently, we conducted the Trial Comparing Cardiovascular Safety of Insulin 
Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of 
Cardiovascular Events (DEVOTE).
METHODS
TRIAL DESIGN AND OVERSIGHT
Detailed methods of the trial have been published previously.10 Briefly, the trial was a treat-
to-target, randomized, double-blind, active comparator–controlled cardiovascular outcomes 
trial that was conducted at 438 sites in 20 countries. The trial was designed to continue until 
the occurrence of at least 633 primary outcome events, as confirmed by central, blinded 
review by an independent event-adjudication committee.
The trial was conducted in accordance with the provisions of the Declaration of Helsinki and 
the International Conference on Harmonisation Good Clinical Practice Guidelines.11,12 The 
protocol (available with the full text of this article at NEJM.org) was approved by the 
independent ethics committee or institutional review board at each trial center. Written 
informed consent was obtained from each patient before any trial-related activities.
The trial was funded and conducted by Novo Nordisk. Statogen Consulting and Novo 
Nordisk both independently analyzed the data only after the database lock. The steering 
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committee, which was composed of the authors, participated in designing the trial, analyzing 
the data, editing an earlier version of the manuscript, and making the decision to submit the 
manuscript for publication. Medical writing and editorial support were funded by the 
sponsor. The authors had full access to all the trial data and vouch for the completeness and 
integrity of the data and for the fidelity of the trial to the protocol.
A prespecified interim analysis was planned, for regulatory purposes as agreed with the 
FDA, to assess the noninferiority of degludec versus glargine for cardiovascular safety after 
the occurrence of 150 primary outcome events, as confirmed by the event-adjudication 
committee.10 Per regulatory guidance, the confirmation of an upper limit of the confidence 
interval below 1.8 at the interim analysis was required to establish non-inferiority and allow 
confidential FDA review.10 On the basis of the results of the submitted interim analysis, the 
FDA approved the use of degludec in the United States in September 2015.
To mitigate the potential risk that an interim analysis posed to the overall integrity of the 
trial, a data-access management plan was developed before the interim analysis and is 
described in detail in the Supplementary Appendix, available at NEJM.org.10 The conduct of 
the trial was overseen by a steering committee that consisted of academic investigators and 
Novo Nordisk employees. In addition, an independent external data and safety monitoring 
committee was established to review accumulated data and evaluate the risk–benefit balance 
at planned intervals. An external independent statistics group, Statistics Collaborative, 
provided unblinded data to the data and safety monitoring committee, which could 
recommend to continue, modify, or terminate the trial prematurely on the basis of criteria 
developed before the initiation of the trial. Operational advice for the trial was provided by 
the global expert panel throughout the trial.
PATIENTS AND TREATMENTS
Patients with type 2 diabetes who were at high risk for cardiovascular events were randomly 
assigned in a 1:1 ratio to receive either degludec or glargine (both in identical 10-ml vials 
containing 100 U per milliliter), with each drug added to standard care and administered 
once daily between dinner and bedtime. Eligible patients included those who were being 
treated with at least one oral or injectable antihyperglycemic agent. Also required was a 
glycated hemoglobin level of 7% or more while the patients were receiving the anti-
hyperglycemic agent; if the level was less than 7%, treatment with at least 20 units of basal 
insulin per day was required. Two groups of patients were eligible for the trial: those who 
were 50 years of age or older who had at least one coexisting cardiovascular or renal 
condition and those who were 60 years of age or older who had at least one cardiovascular 
risk factor. A complete list of inclusion and exclusion criteria is provided in the 
Supplementary Appendix.
Patients could continue their pretrial antihyperglycemic therapy except for basal and premix 
insulins, which were discontinued. Patients adjusted their dose of basal insulin weekly on 
the basis of the lowest of three self-measured blood-glucose values, as measured before 
breakfast 2 days before and on the day of dose adjustment, with the aim of reaching a target 
of 71 to 90 mg per deciliter (4.0 to 5.0 mmol per liter) (Table S1 in the Supplementary 
Appendix). To safeguard vulnerable patients, an alternative blood-glucose target of 90 to 126 
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mg per deciliter (5.0 to 7.0 mmol per liter) was available for these patients. Bolus insulin 
(aspart) was provided by Novo Nordisk for patients who were either continuing or initiating 
bolus treatment during the trial, with weekly adjustments based on the lowest of three 
preprandial or bedtime self-measured blood-glucose values measured on the 3 days before 
dose adjustment and aiming to reach a target of 71 to 126 mg per deciliter (Table S1 in the 
Supplementary Appendix). Higher targets were allowed at the discretion of the investigator.
The following events were adjudicated by the event-adjudication committee in a blinded 
manner: acute coronary syndrome (defined as myocardial infarction or unstable angina 
pectoris leading to hospitalization), stroke, death, and severe hypoglycemia. The definitions 
that were used for the clinical-event adjudication are provided in the Supplementary 
Appendix. Neoplasms were classified by a blinded independent committee as malignant, 
benign, or not classifiable. For neoplasms that were classified as malignant, a further 
subclassification was performed to assess the primary organ site.
OUTCOMES
All outcomes were prespecified unless otherwise stated. The primary composite outcome in 
the time-to-event analysis was the first occurrence of death from cardiovascular causes, 
nonfatal myocardial infarction, or nonfatal stroke. The multiplicity-adjusted confirmatory 
secondary outcomes were the number and incidence of adjudicated events of severe 
hypoglycemia, which was defined by the American Diabetes Association as an episode 
requiring the assistance of another person to actively administer carbohydrate or glucagon or 
to take other corrective actions.13 According to this definition, plasma glucose levels may 
not be available during an event, but neurologic recovery after the return of plasma glucose 
to a normal level is considered to be sufficient evidence that the event was induced by a low 
plasma glucose level.
Other secondary outcomes included an expanded composite cardiovascular outcome (the 
primary composite outcome or unstable angina leading to hospitalization) and the time from 
randomization to death from any cause, along with serious adverse events or adverse events 
leading to discontinuation of the intervention, levels of glycated hemoglobin and fasting 
plasma glucose, blood pressure, pulse, lipid measurements, weight, body-mass index, 
estimated glomerular filtration rate, nocturnal severe hypoglycemia (occurring between 
12:01 a.m. and 5:59 a.m.), and basal and bolus insulin dose. Glycated hemoglobin was 
measured at randomization, at months 3, 6, 9, and 12, and yearly thereafter. Other laboratory 
tests were performed at randomization and yearly thereafter.
STATISTICAL ANALYSIS
The statistical analysis plan is available in the Supplementary Appendix. Details regarding 
the sample-size estimates and statistical analyses have been published previously.10 We 
estimated that the follow-up of 7500 patients for approximately 5 years with an assumed 
event rate of 2.1 per 100 patient-years of exposure would produce 633 events and hence a 
power of 91% to rule on the null hypothesis. A Cox proportional-hazards regression model 
was used to analyze the intention-to-treat population for the primary composite outcome to 
test for the noninferiority of degludec as compared with glargine. Noninferiority would be 
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confirmed if the upper boundary of the 95% confidence interval was less than 1.3. If 
noninferiority was established, we then tested for superiority with respect to severe 
hypoglycemic episodes using a negative binomial-regression model that was adjusted for 
observation time and treatment group to test for the number of events and a logistic-
regression model that was adjusted for treatment group to test for incidence. Superiority of 
these secondary outcomes would be confirmed if the upper boundary of the 95% confidence 
interval was less than 1.0. Selected sensitivity analyses, including the per-protocol analysis, 
were performed to address the robustness of the results. The rationale for the use of a 
noninferiority threshold of 1.3 in the primary analysis and a threshold of 1.8 in the interim 
analysis is described in the Supplementary Appendix.
RESULTS
PATIENTS
From November 2013 through November 2014, a total of 7637 patients were randomly 
assigned to receive either degludec (3818 patients) or glargine (3819 patients) once daily 
(Fig. S1 in the Supplementary Appendix). Of these patients, 98% completed the final 
follow-up visit or died during the trial (Fig. S2 in the Supplementary Appendix). The vital 
status was known for 99.9% of the patients. Five patients (0.06%) were lost to follow-up, 
and three patients (0.04%) had withdrawn consent at the time of the database lock. The 
median observation time was 1.99 years, and the median exposure time was 1.83 years.
The characteristics of the patients at baseline were similar in the two groups (Table S2 in the 
Supplementary Appendix). Of the 7637 patients, 6509 (85.2%) had established 
cardiovascular disease or moderate chronic kidney disease. The mean age was 65.0 years, 
the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin 
level was 8.4±1.7%. Of the 6409 patients (83.9%) who were receiving insulin at baseline, 
3515 (54.8%) were receiving a basal–bolus regimen.
CARDIOVASCULAR OUTCOMES
The primary composite outcome occurred in 325 patients (8.5%) in the degludec group and 
in 356 patients (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval 
[CI], 0.78 to 1.06; P<0.001 for noninferiority in a one-sided test) (Table 1 and Fig. 1A). 
Individual components of the composite cardiovascular outcome are provided in Table 1 and 
Figures 1B, 1C, and 1D. There was no significant difference in the incidence of death in the 
degludec and glargine groups (202 patients [5.3%] vs. 221 patients [5.8%]; hazard ratio, 
0.91; 95% CI, 0.76 to 1.11; P = 0.35).
The results of various sensitivity analyses that used alternative censoring methods were 
aligned with the findings of the primary analysis and are shown, along with the subgroup 
analyses, in Figures S3 and S4 in the Supplementary Appendix. Findings for the remaining 
adjudicated cardiovascular outcomes and the expanded composite outcome are shown in 
Figure S5 in the Supplementary Appendix.
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SEVERE HYPOGLYCEMIA
A total of 752 severe hypoglycemic events occurred, 280 events in 187 patients in the 
degludec group and 472 events in 252 patients in the glargine group; the rate was 3.70 events 
per 100 patient-years in the degludec group and 6.25 events per 100 patient-years in the 
glargine group (rate ratio, 0.60; 95% CI, 0.48 to 0.76; P<0.001 for superiority) (Table 2 and 
Fig. 2A). One or more events of severe hypoglycemia13 occurred in 187 patients (4.9%) in 
the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 
percentage points (odds ratio, 0.73; 95% CI, 0.60 to 0.89; P<0.001 for superiority) (Table 2). 
Of the 752 severe hypoglycemic events that occurred in the two groups, blood-glucose 
measurements were available for 637 events (84.7%) (Fig. S6 in the Supplementary 
Appendix). In addition, there was a lower rate of nocturnal severe hypoglycemia in the 
degludec group than in the glargine group (0.65 vs. 1.40 events per 100 patient-years) for a 
rate ratio of 0.47 (95% CI, 0.31 to 0.73; P<0.001) (Table 2 and Fig. 2B).
The results of the on-treatment analyses were similar to those in the primary analyses (Figs. 
S7 and S8 in the Supplementary Appendix). The results of subgroup analyses are shown in 
Figure S9 in the Supplementary Appendix. Treatment ratios differed significantly in 
subgroups defined according to sex, ethnic group (Hispanic or Latino vs. not Hispanic or 
Latino), cardiovascular risk group (established cardiovascular disease vs. risk factors), and 
trial center (United States vs. other countries in DEVOTE).
GLYCEMIC CONTROL
There was no significant between-group difference in total and bolus insulin dose levels over 
time (Fig. S10 in the Supplementary Appendix). For basal insulin, the estimated dose of 
degludec was 2 units higher than the dose of glargine (estimated treatment ratio, 1.04; 95% 
CI, 1.00 to 1.08; P = 0.04) at 24 months (Fig. S11 in the Supplementary Appendix). Overall 
initiation of concomitant antihyperglycemic medications during the trial was similar in the 
two groups (Table S3 in the Supplementary Appendix).
There also was no significant between-group difference in changes in glycated hemoglobin 
levels throughout the trial (Fig. 2C). At 24 months, the glycated hemoglobin level was 7.5% 
(58 mmol per mole) in the two groups, with an estimated treatment difference of 0.01 
percentage points (95% CI, −0.05 to 0.07; P = 0.78 in post hoc analysis). Over 24 months, 
plasma glucose values that were measured by the patients before breakfast were similar in 
the two groups; the median value for all patients was 95 mg per deciliter (5.3 mmol per liter) 
(Fig. S12 in the Supplementary Appendix).
At 24 months, the mean laboratory-measured fasting plasma glucose level was significantly 
lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter 
[7.1±3.1 vs. 7.5±3.2 mmol per liter]). Laboratory-measured fasting plasma glucose levels 
decreased more in the degludec group than in the glargine group (−39.9 mg per deciliter vs. 
−34.9 mg per deciliter [−2.2 mmol per liter vs. −1.9 mmol per liter]) after 24 months 
(estimated treatment difference, −7.2 mg per deciliter; 95% CI, −10.3 to −4.1 [−0.4 mmol 
per liter; 95% CI, −0.6 to −0.2]; P<0.001 in post hoc analysis) (Fig. 2D).
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CARDIOVASCULAR RISK FACTORS
The observed mean change in cardiovascular risk factors from baseline to month 24 did not 
differ between treatment groups for the following variables: weight, body-mass index, blood 
pressure, pulse, estimated glomerular filtration rate, and all blood lipid levels (high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and 
triglycerides) (Table S4 in the Supplementary Appendix). Changes in the overall use of 
cardiovascular medications during the trial were similar in the two groups (Table S3 in the 
Supplementary Appendix).
SAFETY AND ADVERSE EVENTS
The rate of adverse events was 44.7 events per 100 patient-years in the degludec group and 
50.1 events per 100 patient-years in the glargine group; the corresponding rates of serious 
adverse events were 44.2 events versus 49.6 events per 100 patient-years (Table 3). The rate 
of events leading to permanent discontinuation of a trial drug was 3.7 events per 100 patient-
years in the degludec group and 4.0 events per 100 patient-years in the glargine group. The 
numbers of malignant, benign, and unclassifiable neoplasms were similar in the two groups 
(Table 3, and Table S5 in the Supplementary Appendix). Serious adverse events that 
occurred in at least 1% of the patients and critical symptoms associated with severe 
hypoglycemic episodes (as confirmed by the event-adjudication committee) are described in 
Tables S6, S7, and S8 in the Supplementary Appendix. There were no confirmed fatal events 
associated with hypoglycemia.
DISCUSSION
In this cardiovascular outcomes trial of basal insulin therapy in patients with type 2 diabetes 
at high cardiovascular risk, we found that degludec was noninferior to glargine in terms of 
cardiovascular events and superior with regard to hypoglycemia risk, with a lower rate of 
both severe and nocturnal severe hypoglycemia (by 40% and 53%, respectively; P<0.001 for 
both comparisons). These results were achieved at equivalent glycemic control in the two 
groups. The demonstrated safety of degludec with respect to cardiovascular outcomes was 
reflected in the individual components of the primary composite outcome and was consistent 
across multiple prespecified subgroups.
Patients with diabetes have a greater risk of cardiovascular disease and cardiovascular-
related death than do persons without diabetes.1 Several trials have consequently 
investigated the effect of an intensive reduction in glycemic levels on the risk of 
cardiovascular outcomes in patients with type 2 diabetes.14–17 The results of these trials have 
been varied, with UKPDS, ADVANCE, and VADT showing a neutral effect of reducing 
glycemic levels on the risk of cardiovascular events, whereas ACCORD showed a 
significantly increased risk of death both from cardiovascular causes and from any cause 
associated with more intensive glycemic control.14–17 The focus on cardiovascular outcomes 
related to diabetes treatments was intensified when the FDA issued guidance in 2008 that 
described the need to establish the cardiovascular safety of new antihyperglycemic 
therapies.18 This recommendation led to the conduct of numerous cardiovascular outcomes 
trials involving patients with diabetes.19 Although the FDA guidance did not specifically 
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include various types of insulin, the ORIGIN trial, which was designed before the issuing of 
the FDA guidance and specifically sought to evaluate the cardiovascular safety of glargine, 
showed no significant difference in cardiovascular outcomes with glargine as compared with 
standard care.4 In the context of this complex landscape of cardiovascular outcomes trials, 
we found that degludec was not associated with a greater risk of cardiovascular outcomes 
than was glargine at the same level of glycemic control.
The development of basal insulins with more stable pharmacodynamic profiles has allowed 
patients to aim safely for fasting glucose levels in the normal range by providing a consistent 
glucose-lowering effect with a half-life of more than 24 hours and thereby reducing the 
occurrence of hypoglycemia.20 The reduction in severe hypoglycemia that is reported in our 
trial and in previous trials that have compared degludec with glargine probably results from 
the improved pharmacodynamic profile of degludec.7–9,21
The incidence and rates of severe hypoglycemia across cardiovascular outcomes 
trials4,17,22,23 are difficult to compare owing to differences in the definitions that were used 
and to factors such as frailty, diabetes duration, frequency of insulin use, treatment regimens, 
and treatment targets at baseline and during the trial. Among all the patients in our trial, the 
incidence of severe hypoglycemia (2.90 events per 100 patient-years) and rates (4.97 events 
per 100 patient-years) were within the range that was evident in studies in which the use of 
insulin was a prominent component of therapy, which had a range of incidences from 0.53 to 
5.05 events per 100 patient-years and a range of rates from 0.70 to 8.25 events per 100 
patient-years.4,17,22,23 Severe hypoglycemia is associated with broad negative consequences 
for patients with diabetes.24,25 The number of patients who would need to be treated with 
degludec rather than glargine to avert 1 severe hypoglycemic event is 40.
Our trial has several strengths, including its double-blind design, large enrollment of patients 
at high cardiovascular risk, and high retention rate of patients. The primary limitation of the 
trial is its intermediate duration (2 years). Whether these findings can be extrapolated to 
longer exposure, to patients with a lower risk of cardiovascular events, or both is uncertain. 
Furthermore, no adjustments were made for multiplicity in the exploratory analysis beyond 
the prespecified hierarchical analyses of the cardiovascular outcomes and severe 
hypoglycemia. Overall, the exploratory analyses support the results for the primary and 
secondary outcomes. However, it is important to emphasize that these analyses are 
exploratory and have not been adjusted for multiple testing.26–28
In conclusion, we found that in patients with type 2 diabetes at high risk for cardiovascular 
events, degludec was noninferior to glargine in terms of the incidence of cardiovascular 
events.
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Figure 1. Kaplan–Meier Analysis of the Composite Primary Outcome
Shown are plots of time until the primary outcome (Panel A) and its composite events — 
death from cardiovascular causes (Panel B), nonfatal myocardial infarction (Panel C), and 
nonfatal stroke (Panel D) — in the degludec group and the glargine group. The 
noninferiority of degludec as compared with glargine was confirmed because the upper limit 
of the two-sided 95% confidence interval for the hazard ratio was less than 1.3. The results 
were determined by the event-adjudication committee on the basis of Cox proportional-
hazards regression analysis in the intention-to-treat population. Data for patients without an 
event were censored at the time of the last contact (telephone or visit). The inset graphs 
show the same data on expanded y axes.
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Figure 2. Severe Hypoglycemia and Glucose Control
Shown are the observed cumulative number of events of severe hypoglycemia (Panel A) and 
nocturnal severe hypoglycemia (Panel B) per patient in the degludec group and the glargine 
group. For severe hypoglycemia, the superiority of degludec over glargine was confirmed 
because the upper limit of the two-sided 95% confidence interval for the estimated rate ratio 
was below 1.0. Nocturnal severe hypoglycemia was defined as an episode with an 
investigator-reported onset between 12:01 a.m. and 5:59 a.m. Also shown are measures of 
treatment efficacy, according to the glycated hemoglobin level (Panel C) and the fasting 
plasma glucose level (Panel D) in the two groups, with both comparisons performed in post 
hoc analyses.
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